114
Participants
Start Date
April 1, 2018
Primary Completion Date
July 30, 2025
Study Completion Date
December 30, 2025
Olaparib
olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center Westchester, East White Plains
Memorial Sloan Kettering Cancer Center Nassau, Uniondale
Memorial Sloan Kettering Cancer Center Commack, Commack
University of Pittsburgh, Pittsburgh
UPMC Hillman Cancer Center - Erie, Erie
University of Pennsylvania, Philadelphia
Johns Hopkins University, Baltimore
Duke University, Durham
University of Alabama at Birmingham, Birmingham
Indiana University, Indianapolis
University of Chicago, Chicago
University of California, San Francisco, San Francisco
University of Washington Fred Hutchinson Cancer Care, Seattle
Beth Israel Deaconess Medical Center, Boston
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge
Memorial Sloan Kettering Cancer Center Monmouth, Middletown
Memorial Sloan Kettering Cancer Center Bergen, Montvale
Collaborators (1)
Johns Hopkins University
OTHER
AstraZeneca
INDUSTRY
Dana-Farber Cancer Institute
OTHER
Beth Israel Deaconess Medical Center
OTHER